(B) Plau-004 mRNA expression in MDA-MB231 cells. Pol II is not recruited only at the Plau-001 TSS but also upstream in the ABR-1.9 and ABR-4.1 region. Most Pol II molecules transcribe short and unstable RNAs while tracking down toward the TSS, where there are converted into Plau-001 mRNA-productive species. Moreover, a minority of Pol II molecules transcribes a low abundance mRNA of unknown function called Plau-004 from the ABR-1.9 domain, whose expression is tempered by Fra-1. Thus, we unveil a heretofore-unsuspected transcriptional complexity at Plau in a reference metastatic breast cancer cell line with pleiotropic effects for Fra-1, providing novel information on AP-1 transcriptional action. INTRODUCTION The uPA urokinase-type plasminogen activator protease is overexpressed in many cancer cells, including breast carcinomas, where it plays a crucial role Teriflunomide in the metastatic process (1C3). Recently, guidelines from the American Society of Clinical Oncology recommended the dosage of uPA for risk assessment and treatment decision for node negative breast cancer, as high levels of uPA are associated with poor outcome (4). The transcriptional mechanisms underlying uPA gene (also known as Plau) overexpression in metastatic tumors are, however, still Teriflunomide unknown, though a role for the AP-1 transcriptional complex in the transcriptional regulation of Plau has been proposed in diverse experimental systems (5C10). AP-1 is an ubiquitous family of dimeric transcription factors that controls virtually all important cell decisions due to binding to so-called AP-1/TRE or CRE DNA motifs found in a wide variety of genes (11,12). AP-1 is principally made up of the members of the Fos (c-Fos, FosB, Fra-1 and Fra-2) and Jun (c-Jun, JunB and JunD) families (11,12). In contrast to Fos proteins, which must heterodimerize with transcription partners, such as the Jun proteins, the Jun proteins can also homodimerize even though LAMA5 their heterodimerization with Fos proteins is favored (11C16). AP-1 protein abundance and activity are controlled by intermingled transcriptional and post-transcriptional mechanisms, which are themselves regulated by intracellular signaling (17C19). Despite an abundant literature on their biological functions and the cell signaling converging onto them, the mechanisms whereby the different Fos and Jun dimers regulate transcription are surprisingly still poorly understood. Besides its physiological roles, AP-1 is also Teriflunomide frequently altered in cancer where it participates to tumorigenesis (14,15,20C22). Of particular interest here is the Fos family protein Fra-1, which has been shown to contribute to metastasis, invasiveness, cell motility, cell division and protection from apoptosis in diverse epithelial cancers affecting breast, ovary, thyroid, lung, bladder or colon (23C31). Its best documented pathological effects, however, concern breast carcinomas where several authors have proposed that Fra-1 might constitute a useful diagnosis marker (30) and/or a target for cancer prevention or intervention (28,31C33). More Teriflunomide specifically, (i) Fra-1 accumulates to high levels in cell nuclei from ductal and lobular carcinomas, which contrasts with its absence in normal breast tissues and its shared cytoplasmic and nuclear distribution in a small fraction of fibroadenoma cells (30), (ii) RNAi depletion of Fra-1 in an aggressive breast cancer cell line decreases invasiveness and reverts the mesenchymal phenotype (25), (iii) Estrogen Receptor negative (ER?) tumors, which are more metastatic and of poorer prognosis than the Estrogen Receptor positive (ER+) ones, show a higher AP-1 activity essentially contributed by higher levels of hyperphosphorylated Fra-1 (25,26,32) and (iv) shRNA-mediated suppression of Fra-1 expression abrogates the metastatic potential of an aggressive human breast cancer cell line in nude mice (31). As Fra-1 is expressed to high levels in metastatic mammary tumors where uPA (Plau) is also overexpressed and as the Plau gene was demonstrated to be an AP-1 target in other situations, we have addressed here whether Fra-1 could deregulate Plau in such cancers using RNAi-, pharmacological- and locus-wide chromatin immunoprecipitation (ChIP) analyses in a reference metastatic breast cancer cell line. Our work unveils Teriflunomide a novel and unsuspected transcriptional complexity at the Plau locus under.